ProKidney Future Growth

Future criteria checks 0/6

ProKidney's earnings are forecast to decline at 10.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to decline by 4.2% per annum. Return on equity is forecast to be -47.1% in 3 years.

Key information

-10.7%

Earnings growth rate

-4.2%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	82.4%
Future return on equity	-47.1%
Analyst coverage	Low
Last updated	21 Nov 2024

Recent future growth updates

Recent updates

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Nov 17

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Mar 14

ProKidney reports Q2 2022 results

Aug 11

Earnings and Revenue Growth Forecasts

NasdaqCM:PROK - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-107	-216	-160	3
12/31/2025	N/A	-73	-177	-150	3
12/31/2024	N/A	-58	-127	-102	3
9/30/2024	N/A	-46	-133	-128	N/A
6/30/2024	N/A	-39	-153	-122	N/A
3/31/2024	N/A	-35	-133	-99	N/A
12/31/2023	N/A	-35	-124	-90	N/A
9/30/2023	N/A	-36	-113	-80	N/A
6/30/2023	N/A	-33	-85	-80	N/A
3/31/2023	N/A	43	-90	-88	N/A
12/31/2022	N/A	-14	-79	-77	N/A
9/30/2022	N/A	-22	-76	-74	N/A
6/30/2022	N/A	-31	-73	-70	N/A
3/31/2022	N/A	-111	-63	-59	N/A
12/31/2021	N/A	-55	-55	-50	N/A
9/30/2021	N/A	-49	-52	-45	N/A
12/31/2020	N/A	-27	-31	-25	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PROK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PROK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PROK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PROK is forecast to have no revenue next year.

High Growth Revenue: PROK is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PROK is forecast to be unprofitable in 3 years.

ProKidney Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 24% to US$4.83

Price target decreased by 19% to US$12.50

Recent updates

We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely

Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Prokidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S

New minor risk - Shareholder dilution

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

New minor risk - Shareholder dilution

ProKidney Corp. has completed a Follow-on Equity Offering in the amount of $26.693989 million.

New minor risk - Shareholder dilution

ProKidney Corp. Announces Positive Interim Regen-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Price target decreased by 24% to US$4.83

Chief Reg. Off notifies of intention to sell stock

We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth

ProKidney Corp., Annual General Meeting, May 30, 2024

New major risk - Share price stability

Chief Reg. Off notifies of intention to sell stock

ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

ProKidney Corp. Announces Termination of Deepak Jain as Chief Operating Officer

Prokidney Appoints Nikhil Pereira-Kamath as Chief Business Officer

ProKidney Corp. (NasdaqCM:PROK) announces an Equity Buyback for 7,256,367 shares, for $9.5 million.

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Price target decreased by 19% to US$12.50

ProKidney Corp. Announces Executive Changes

ProKidney Corp. Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 20%

Investor sentiment deteriorates as stock falls 20%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

ProKidney Corp. Announces the Appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

Now 24% undervalued

Investor sentiment improves as stock rises 15%

ProKidney Corp., Annual General Meeting, Jun 29, 2023

Investor sentiment improves as stock rises 19%

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Libbie McKenzie Resigns from Prokidney as Chief Medical Officer

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of React for Late Stage 4 Diabetes-Related Chronic Kidney Disease

High number of new directors

ProKidney Corp. Appoints Glenn Schulman as Senior Vice President of Investor Relations

ProKidney Corp. Announces Board Appointments

ProKidney reports Q2 2022 results

ProKidney Corp. Appoints Kerry Cooper as Senior Vice President of Medical Affairs

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies